Gilead Sciences Slashes 2026 Guidance, Projecting Loss on R&D Costs

Key Facts

Gilead Sciences has announced a significant downward revision to its 2026 financial guidance, now projecting an adjusted loss between $0.65 and $1.05 per share. This revision comes despite the company beating Q1 estimates, a performance primarily driven by robust growth in HIV drug sales and the oncology treatment Trodelvy. The shift marks a dramatic reversal from previous earnings estimates of $8.45 to $8.85 per share, triggering an immediate negative reaction in the stock price. Gilead identified Ono Pharmaceutical as the key partner in the R&D collaboration responsible for the substantial charges. Analysts are now evaluating whether the long-term potential of the Ono partnership can offset these significant near-term costs. This update underscores the high capital intensity and financial risks inherent in developing innovative biotech pipelines.

Version History